Published in Clin Cancer Res on October 01, 2008
Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer | NCT00208273
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Radiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic function by TGF-beta1-mediated tissue fibrosis. Am J Physiol Cell Physiol (2010) 1.09
Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics (2011) 1.07
Reduction of radiation pneumonitis by V20-constraints in breast cancer. Radiat Oncol (2010) 0.97
STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiother Oncol (2013) 0.97
Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med (2011) 0.95
Prediction of clinical toxicity in localized cervical carcinoma by radio-induced apoptosis study in peripheral blood lymphocytes (PBLs). Radiat Oncol (2009) 0.92
SNPs in genes implicated in radiation response are associated with radiotoxicity and evoke roles as predictive and prognostic biomarkers. Radiat Oncol (2013) 0.91
Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial. EBioMedicine (2015) 0.89
Single-nucleotide polymorphisms in BER and HRR genes, XRCC1 haplotypes and breast cancer risk in Caucasian women. J Cancer Res Clin Oncol (2010) 0.89
A bioinformatics filtering strategy for identifying radiation response biomarker candidates. PLoS One (2012) 0.86
Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol Ther (2010) 0.86
Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity? Cancer Lett (2016) 0.85
Radiation-induced fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol (2015) 0.84
Association between Single Nucleotide Polymorphisms in XRCC3 and Radiation-Induced Adverse Effects on Normal Tissue: A Meta-Analysis. PLoS One (2015) 0.80
Biological complexities in radiation carcinogenesis and cancer radiotherapy: impact of new biological paradigms. Genes (Basel) (2012) 0.79
Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients. Strahlenther Onkol (2011) 0.79
Association of XRCC1 and XRCC3 gene haplotypes with the development of radiation-induced fibrosis in patients with nasopharyngeal carcinoma. Mol Clin Oncol (2014) 0.77
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
No association between TGFB1 polymorphisms and late radiotherapy toxicity: a meta-analysis. PLoS One (2013) 0.76
Multidisciplinary approach of early breast cancer: the biology applied to radiation oncology. Radiat Oncol (2010) 0.76
Single Nucleotide Polymorphism rs1801516 in Ataxia Telangiectasia-Mutated Gene Predicts Late Fibrosis in Cancer Patients After Radiotherapy: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine (Baltimore) (2016) 0.76
Among 45 variants in 11 genes, HDM2 promoter polymorphisms emerge as new candidate biomarker associated with radiation toxicity. 3 Biotech (2013) 0.75
Radiation Induced Lymphocyte Apoptosis: An Effective Way of "Tailoring" Radiotherapy to the Right Patients Only? EBioMedicine (2015) 0.75
GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clin Genitourin Cancer (2015) 0.75
One Size Fits All: Does the Dogma Stand in Radiation Oncology? EBioMedicine (2016) 0.75
SIX1 overexpression predicts poor prognosis and induces radioresistance through AKT signaling in esophageal squamous cell carcinoma. Onco Targets Ther (2017) 0.75
Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial†. Ann Oncol (2015) 0.75
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys (1995) 15.12
Mutation detection using Surveyor nuclease. Biotechniques (2004) 3.72
Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol (2003) 3.70
Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer (2006) 3.65
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res (2006) 2.68
Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol (2003) 2.26
Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol (2007) 1.83
TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol (2005) 1.78
Altered apoptotic profiles in irradiated patients with increased toxicity. Int J Radiat Oncol Biol Phys (1999) 1.73
Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med (2006) 1.55
Responses of normal cells to ionizing radiation. Semin Radiat Oncol (2007) 1.38
Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev (2003) 1.33
CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res (2005) 1.32
Surveyor Nuclease: a new strategy for a rapid identification of heteroplasmic mitochondrial DNA mutations in patients with respiratory chain defects. Hum Mutat (2005) 1.31
ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys (2002) 1.18
A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Cancer J Sci Am (1999) 1.17
Temperature-mediated heteroduplex analysis for the detection of drug-resistant gene mutations in clinical isolates of Mycobacterium tuberculosis by denaturing HPLC, SURVEYOR nuclease. Microbes Infect (2005) 1.13
Latent-TGF-beta: an overview. Mol Cell Biochem (2001) 1.12
Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys (2006) 1.10
Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys (2001) 1.05
Rapid assay of intrinsic radiosensitivity based on apoptosis in human CD4 and CD8 T-lymphocytes. Int J Radiat Oncol Biol Phys (1997) 1.05
Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: implication in radiation-induced vascular damages. Am J Pathol (2006) 1.05
Sources of variation in patient response to radiation treatment. Int J Radiat Oncol Biol Phys (2001) 0.99
Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer (2004) 0.94
A versatile and rapid assay of radiosensitivity of peripheral blood leukocytes based on DNA and surface-marker assessment of cytotoxicity. Radiat Res (1997) 0.93
Radiation-induced side effects with or without systemic therapies: prime time for prediction of individual radiosensitivity. Int J Radiat Oncol Biol Phys (2008) 0.80
Radiation therapy and tamoxifen: concurrent or sequential? It's no longer the question! J Clin Oncol (2005) 0.79
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 10.17
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol (2010) 4.61
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol (2009) 2.88
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol (2012) 2.62
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol (2013) 2.39
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol (2006) 2.32
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol (2004) 2.29
Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality. J Biotechnol (2006) 2.12
Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas (2008) 2.05
Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res (2004) 2.03
Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys (2007) 2.02
Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol (2009) 1.94
Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst (2010) 1.91
Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol (2008) 1.88
Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev (2005) 1.85
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol (2010) 1.83
Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys (2012) 1.83
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol (2009) 1.81
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Intraoperative radiotherapy in early-stage breast cancer: results of the montpellier phase II trial. Int J Radiat Oncol Biol Phys (2009) 1.69
Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother Oncol (2013) 1.68
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer (2006) 1.68
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol (2008) 1.65
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol (2010) 1.65
TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.64
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol (2007) 1.63
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. Eur J Cancer (2008) 1.61
Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys (2013) 1.61
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol (2007) 1.60
Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol (2012) 1.59
Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer (2008) 1.58
Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys (2008) 1.58
Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res (2005) 1.56
Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta (2008) 1.54
Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment. Int J Radiat Oncol Biol Phys (2004) 1.50
Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol (2007) 1.47
Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J Nucl Med (2010) 1.45
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res (2007) 1.43
Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys (2005) 1.42
Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol (2008) 1.41
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol (2002) 1.40
Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol (2003) 1.40
Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.39
[White paper on radiation oncology in France. Twelve proposals to improve a major cancer treatment. Société française de radiothérapie oncologique]. Cancer Radiother (2013) 1.39
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res (2007) 1.35
Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat (2003) 1.33
CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res (2005) 1.32
Techniques and pitfalls in the detection of pathogenic mitochondrial DNA mutations. J Mol Diagn (2003) 1.32
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics (2009) 1.31
Thymoma: a focus on current therapeutic management. J Thorac Oncol (2009) 1.29
Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer. Radiat Oncol (2010) 1.25
Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res (2004) 1.25
Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys (2010) 1.23
Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res (2009) 1.23
Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol (2007) 1.23
Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol (2010) 1.22
Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys (2006) 1.22
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol (2012) 1.22
ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys (2002) 1.18
Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models. Crit Rev Oncol Hematol (2012) 1.18
Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study. Radiother Oncol (2006) 1.17
Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res (2008) 1.16
CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res (2008) 1.15
Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys (2006) 1.14
Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int J Radiat Oncol Biol Phys (2010) 1.14
The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol (2006) 1.13
Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother (2010) 1.12
Radiotherapy options after breast-conserving surgery: how can selection of patients be refined? J Clin Oncol (2013) 1.12
The reasons for discrepancies in target volume delineation : a SASRO study on head-and-neck and prostate cancers. Strahlenther Onkol (2006) 1.11
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys (2006) 1.10
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist (2011) 1.09
Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res (2004) 1.09
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem (2011) 1.08
The Rare Cancer Network: achievements from 1993 to 2012. Rare Tumors (2012) 1.08
Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study. Int J Radiat Oncol Biol Phys (2011) 1.07
Management of adenoid cystic carcinoma of the breast: a Rare Cancer Network study. Int J Radiat Oncol Biol Phys (2011) 1.07
Multiple mechanisms of reduced major histocompatibility complex class II expression in endotoxin tolerance. J Biol Chem (2003) 1.06